Multiple Myeloma

>

Latest News

Complete response rate strongly correlated with lower SLiM-CRAB incidence and biochemical progression in those with high-risk smoldering multiple myeloma.
Response Depth in High-Risk Smoldering Multiple Myeloma May Predict Outcomes

January 24th 2025

Complete response rate strongly correlated with lower SLiM-CRAB incidence and biochemical progression in those with high-risk smoldering multiple myeloma.

Isatuximab Combo Approved in EU for Transplant-Ineligible NDMM
Isatuximab Combo Approved in EU for Transplant-Ineligible NDMM

January 22nd 2025

Additionally, the Chinese Society of Clinical Oncology and Chinese Anti-Cancer Association guidelines recommend the isatuximab regimen for this population.
Isatuximab Combo Earns Chinese Approval in R/R Multiple Myeloma

January 16th 2025

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma
Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

January 9th 2025

Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.
Data Show Enduring Efficacy with Anito-cel in R/R Multiple Myeloma

December 30th 2024